Already have an account? Sign in.
AppLovin Climbs as Citi Says Tumble is a Buying Opportunity
SEC is probing AppLovin’s data. Stock fell, but Citi analysts call the drop "extreme" and urge investors to buy the shares now.
SEC is probing AppLovin’s data. Stock fell, but Citi analysts call the drop "extreme" and urge investors to buy the shares now.
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
Arm reported record Q2 revenue of $1.44 billion, up 27% year over year, driven by strong licensing growth and rising AI-related demand.
Record third-quarter results show AppLovin revenue up 55% to $2.18B and net income up 72% to $1.44B, alongside raised fourth-quarter guidance.
Be the first to know when deals break, stocks move, or biotech headlines hit.